SecBot SecBot
424B5 ·Filed Jun 3, 2026

NRXPW

NRX Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago SEC0001437749-26-019368
Notable filing: 424B5
Actionable Insight ▼ Bearish

The steep discount and significant dilution signal near-term selling pressure. Monitor for potential further capital needs given the going-concern audit language and the company's clinical-stage status with no approved products. The 60-day lock-up expiration could add additional supply.

DirectionBearish
Confidencehigh
Horizondays

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 per share, raising approximately $18.8 million in net proceeds (or ~$21.6 million if the underwriters' over-allotment option is fully exercised). The offering price represents a ~24% discount to the last closing price of $4.62 on June 2, 2026. Proceeds are earmarked for working capital and general corporate purposes. The filing also discloses a negative tangible book value of $(0.49) per share as of March 31, 2026, with new investors facing immediate dilution of $3.44 per share.

Key Facts

  • Offering of 5,714,286 shares of common stock at $3.50 per share (24% discount to $4.62 close on June 2, 2026)
  • Net proceeds of ~$18.8 million (or ~$21.6 million if over-allotment fully exercised)
  • Pro forma net tangible book value per share after offering: $0.06, vs. $(0.49) before offering
  • Immediate dilution of $3.44 per share for new investors
  • Underwriters: BTIG (lead) and Lucid Capital Markets
  • Lock-up agreements: officers, directors, and company subject to 60-day lock-up
  • Auditors' reports include going-concern explanatory paragraphs for FY2024 and FY2025
  • Outstanding warrants: 9,359,710 shares at $7.77 weighted average exercise price

Financial Impact

~$18.8M net proceeds raised at a 24% discount to market, with $3.44/share dilution for new investors

dilutionshare countcash balance

Risk Factors

  • Immediate 24% discount to market price creates arbitrage opportunity for new investors
  • Going-concern qualification in audited financials indicates high cash burn risk
  • Substantial warrant overhang (9.36M shares at $7.77) may pressure stock if exercised
  • Management has broad discretion over use of proceeds with no specific allocation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001437749-26-019368
Document: 0001437749-26-019368-index-headers.html0001437749-26-019368
Document: 0001437749-26-019368-index.html0001437749-26-019368
Document: 0001437749-26-019368.txt0001437749-26-019368

Track record

4 reports on NRXPW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 4, 202623w ago 8-K Bearish 6/10 No price data
  2. Jun 3, 202623w ago 424B5 Bearish 6/10 Viewing No price data
  3. Jun 2, 202623w ago 424B5 Bearish 6/10 No price data
  4. May 22, 202625w ago 25-NSE Bearish 8/10 Entry $0.0142 to $0.0142 · 0.00% +1.21% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026